 Roy Parker
Concepts (262)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytoplasmic Granules | 16 | 2024 | 74 | 7.790 |
Why?
| | Ribonucleoproteins | 15 | 2025 | 103 | 5.780 |
Why?
| | RNA | 14 | 2025 | 940 | 3.960 |
Why?
| | tau Proteins | 5 | 2025 | 115 | 3.250 |
Why?
| | RNA-Binding Proteins | 12 | 2025 | 462 | 2.810 |
Why?
| | RNA Stability | 11 | 2024 | 119 | 2.740 |
Why?
| | RNA, Messenger | 18 | 2024 | 2832 | 2.610 |
Why?
| | Saccharomyces cerevisiae | 6 | 2020 | 579 | 2.320 |
Why?
| | Protein Aggregation, Pathological | 4 | 2025 | 22 | 2.130 |
Why?
| | Tauopathies | 3 | 2025 | 17 | 2.120 |
Why?
| | Exoribonucleases | 4 | 2023 | 45 | 2.010 |
Why?
| | Stress, Physiological | 7 | 2025 | 453 | 1.980 |
Why?
| | DEAD-box RNA Helicases | 5 | 2026 | 90 | 1.950 |
Why?
| | RNA, Fungal | 4 | 2020 | 73 | 1.720 |
Why?
| | Protein Aggregates | 2 | 2025 | 86 | 1.710 |
Why?
| | RNA, Double-Stranded | 5 | 2025 | 56 | 1.580 |
Why?
| | Dyskeratosis Congenita | 4 | 2023 | 7 | 1.580 |
Why?
| | Eukaryotic Cells | 6 | 2019 | 40 | 1.520 |
Why?
| | Virus Replication | 5 | 2026 | 529 | 1.370 |
Why?
| | Cell Nucleus | 3 | 2025 | 618 | 1.320 |
Why?
| | Transcriptome | 4 | 2024 | 1045 | 1.290 |
Why?
| | Eukaryotic Initiation Factor-2 | 2 | 2019 | 33 | 1.130 |
Why?
| | Intrinsically Disordered Proteins | 3 | 2018 | 43 | 1.090 |
Why?
| | Saccharomyces cerevisiae Proteins | 4 | 2020 | 419 | 1.060 |
Why?
| | MicroRNAs | 4 | 2023 | 701 | 1.030 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 529 | 1.010 |
Why?
| | Peptide Chain Initiation, Translational | 2 | 2019 | 45 | 0.980 |
Why?
| | Amyloid | 2 | 2018 | 92 | 0.970 |
Why?
| | Neurodegenerative Diseases | 3 | 2025 | 151 | 0.950 |
Why?
| | RNA Processing, Post-Transcriptional | 3 | 2025 | 92 | 0.950 |
Why?
| | RNA Viruses | 2 | 2019 | 76 | 0.940 |
Why?
| | Receptors, Pattern Recognition | 1 | 2025 | 12 | 0.930 |
Why?
| | Retinoblastoma Protein | 1 | 2025 | 61 | 0.910 |
Why?
| | Myotonic Dystrophy | 1 | 2025 | 10 | 0.890 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2025 | 112 | 0.890 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2025 | 44 | 0.890 |
Why?
| | Coiled Bodies | 1 | 2025 | 9 | 0.880 |
Why?
| | Antiviral Agents | 3 | 2026 | 767 | 0.870 |
Why?
| | Imidazoles | 1 | 2026 | 254 | 0.860 |
Why?
| | Nucleic Acids | 1 | 2025 | 72 | 0.860 |
Why?
| | Endoribonucleases | 3 | 2021 | 80 | 0.850 |
Why?
| | Animals | 27 | 2025 | 38058 | 0.840 |
Why?
| | Protein Biosynthesis | 4 | 2019 | 458 | 0.830 |
Why?
| | RNA Helicases | 2 | 2024 | 31 | 0.830 |
Why?
| | Cell Nucleus Structures | 1 | 2023 | 4 | 0.820 |
Why?
| | RNA, Untranslated | 2 | 2023 | 124 | 0.810 |
Why?
| | HeLa Cells | 6 | 2024 | 650 | 0.790 |
Why?
| | Cell Hypoxia | 1 | 2024 | 247 | 0.780 |
Why?
| | Alzheimer Disease | 2 | 2021 | 621 | 0.780 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2608 | 0.780 |
Why?
| | Telomerase | 2 | 2022 | 248 | 0.740 |
Why?
| | Viral Load | 3 | 2021 | 526 | 0.740 |
Why?
| | Organelles | 3 | 2020 | 57 | 0.730 |
Why?
| | Humans | 45 | 2026 | 144759 | 0.710 |
Why?
| | Viruses | 1 | 2024 | 165 | 0.700 |
Why?
| | Virus Diseases | 1 | 2024 | 216 | 0.690 |
Why?
| | RNA, Small Nucleolar | 1 | 2021 | 8 | 0.680 |
Why?
| | 3' Untranslated Regions | 2 | 2019 | 152 | 0.680 |
Why?
| | Carrier Proteins | 1 | 2024 | 737 | 0.650 |
Why?
| | Influenza A virus | 1 | 2021 | 113 | 0.640 |
Why?
| | Immunity, Innate | 2 | 2025 | 846 | 0.640 |
Why?
| | Muscular Diseases | 1 | 2020 | 108 | 0.630 |
Why?
| | Eukaryotic Initiation Factor-4A | 1 | 2020 | 6 | 0.630 |
Why?
| | Eukaryotic Initiation Factor-4F | 1 | 2020 | 4 | 0.630 |
Why?
| | Muscle Development | 1 | 2020 | 116 | 0.630 |
Why?
| | RNA Splicing | 3 | 2021 | 284 | 0.630 |
Why?
| | Macrophages | 2 | 2025 | 1511 | 0.610 |
Why?
| | RNA Virus Infections | 1 | 2019 | 20 | 0.610 |
Why?
| | eIF-2 Kinase | 1 | 2019 | 29 | 0.610 |
Why?
| | Prostaglandin D2 | 1 | 2019 | 22 | 0.580 |
Why?
| | Interferon-beta | 1 | 2019 | 92 | 0.580 |
Why?
| | TDP-43 Proteinopathies | 1 | 2018 | 6 | 0.580 |
Why?
| | DNA | 1 | 2025 | 1463 | 0.570 |
Why?
| | Cellular Reprogramming | 1 | 2019 | 103 | 0.570 |
Why?
| | Neuromuscular Diseases | 1 | 2020 | 146 | 0.570 |
Why?
| | Vault Ribonucleoprotein Particles | 1 | 2017 | 1 | 0.540 |
Why?
| | Open Reading Frames | 1 | 2018 | 132 | 0.540 |
Why?
| | Protein Binding | 6 | 2025 | 2273 | 0.530 |
Why?
| | Macromolecular Substances | 1 | 2018 | 224 | 0.520 |
Why?
| | Single Molecule Imaging | 1 | 2017 | 46 | 0.520 |
Why?
| | Ribosomes | 2 | 2018 | 191 | 0.500 |
Why?
| | RNA Caps | 1 | 2016 | 33 | 0.500 |
Why?
| | Regeneration | 1 | 2018 | 197 | 0.500 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2017 | 322 | 0.490 |
Why?
| | Muscular Atrophy, Spinal | 1 | 2016 | 25 | 0.480 |
Why?
| | Mass Screening | 3 | 2021 | 1347 | 0.470 |
Why?
| | Protein Processing, Post-Translational | 3 | 2025 | 477 | 0.470 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 549 | 0.470 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2015 | 11 | 0.460 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3540 | 0.460 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 267 | 0.460 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2015 | 76 | 0.450 |
Why?
| | Inflammation | 2 | 2024 | 2878 | 0.440 |
Why?
| | Nervous System Diseases | 1 | 2018 | 284 | 0.440 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 162 | 0.440 |
Why?
| | Viroids | 1 | 2014 | 6 | 0.440 |
Why?
| | TATA-Binding Protein Associated Factors | 1 | 2014 | 22 | 0.440 |
Why?
| | RNA-Binding Protein FUS | 1 | 2014 | 15 | 0.440 |
Why?
| | RNA, Viral | 2 | 2019 | 688 | 0.430 |
Why?
| | RNA, Small Nuclear | 1 | 2014 | 38 | 0.420 |
Why?
| | Phosphorylation | 3 | 2025 | 1732 | 0.370 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1782 | 0.370 |
Why?
| | Nuclear Proteins | 3 | 2023 | 748 | 0.360 |
Why?
| | Mice | 7 | 2025 | 18339 | 0.360 |
Why?
| | Drosophila Proteins | 1 | 2014 | 212 | 0.360 |
Why?
| | Drosophila melanogaster | 1 | 2014 | 236 | 0.360 |
Why?
| | Muscle, Skeletal | 2 | 2020 | 1795 | 0.350 |
Why?
| | Protein Folding | 3 | 2018 | 279 | 0.350 |
Why?
| | Active Transport, Cell Nucleus | 3 | 2018 | 121 | 0.350 |
Why?
| | DNA-Binding Proteins | 1 | 2018 | 1499 | 0.340 |
Why?
| | Proteome | 1 | 2016 | 518 | 0.330 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2025 | 214 | 0.330 |
Why?
| | Models, Biological | 5 | 2019 | 1821 | 0.320 |
Why?
| | Mutation | 5 | 2022 | 4089 | 0.310 |
Why?
| | Cytosol | 2 | 2021 | 227 | 0.310 |
Why?
| | Polyadenylation | 2 | 2020 | 41 | 0.300 |
Why?
| | Cell Survival | 2 | 2025 | 1098 | 0.300 |
Why?
| | Neurons | 1 | 2018 | 1640 | 0.290 |
Why?
| | Mammals | 2 | 2022 | 293 | 0.280 |
Why?
| | Protein Interaction Maps | 2 | 2018 | 51 | 0.270 |
Why?
| | HEK293 Cells | 2 | 2021 | 744 | 0.260 |
Why?
| | Models, Theoretical | 2 | 2021 | 582 | 0.260 |
Why?
| | Azepines | 1 | 2026 | 107 | 0.230 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 1 | 2025 | 3 | 0.220 |
Why?
| | RNA Recognition Motif Proteins | 1 | 2024 | 5 | 0.220 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2024 | 36 | 0.220 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1054 | 0.220 |
Why?
| | Ribosomal Proteins | 1 | 2025 | 91 | 0.210 |
Why?
| | Recombinant Proteins | 2 | 2020 | 1370 | 0.210 |
Why?
| | Asymptomatic Infections | 2 | 2021 | 37 | 0.210 |
Why?
| | Drosophila | 1 | 2025 | 166 | 0.210 |
Why?
| | Cell Nucleolus | 1 | 2023 | 20 | 0.200 |
Why?
| | Protein Domains | 1 | 2025 | 313 | 0.200 |
Why?
| | Loss of Function Mutation | 1 | 2023 | 46 | 0.200 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2023 | 53 | 0.200 |
Why?
| | DNA Helicases | 1 | 2024 | 143 | 0.200 |
Why?
| | Molecular Chaperones | 1 | 2024 | 200 | 0.190 |
Why?
| | Mitosis | 1 | 2024 | 200 | 0.190 |
Why?
| | Molecular Docking Simulation | 1 | 2023 | 124 | 0.190 |
Why?
| | Neutropenia | 1 | 2023 | 155 | 0.190 |
Why?
| | Virion | 2 | 2021 | 111 | 0.190 |
Why?
| | Host-Pathogen Interactions | 1 | 2025 | 371 | 0.180 |
Why?
| | Cell Cycle | 1 | 2025 | 596 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 427 | 0.180 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5992 | 0.170 |
Why?
| | Biology | 1 | 2022 | 91 | 0.170 |
Why?
| | Time Factors | 3 | 2021 | 7173 | 0.170 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 175 | 0.170 |
Why?
| | Nidovirales | 1 | 2020 | 1 | 0.170 |
Why?
| | Orthoreovirus | 1 | 2020 | 6 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2021 | 86 | 0.160 |
Why?
| | Limit of Detection | 1 | 2021 | 97 | 0.160 |
Why?
| | Carrier State | 1 | 2021 | 79 | 0.160 |
Why?
| | Lizards | 1 | 2020 | 46 | 0.160 |
Why?
| | Calibration | 1 | 2021 | 151 | 0.160 |
Why?
| | Cell Line | 1 | 2026 | 2882 | 0.160 |
Why?
| | Reoviridae Infections | 1 | 2020 | 55 | 0.160 |
Why?
| | Mice, Transgenic | 1 | 2025 | 2182 | 0.160 |
Why?
| | Kinetics | 2 | 2021 | 1627 | 0.160 |
Why?
| | Time-Lapse Imaging | 1 | 2020 | 22 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 881 | 0.150 |
Why?
| | Vero Cells | 1 | 2019 | 84 | 0.150 |
Why?
| | A549 Cells | 1 | 2019 | 75 | 0.150 |
Why?
| | Epidemics | 1 | 2021 | 98 | 0.150 |
Why?
| | Protein Transport | 1 | 2021 | 441 | 0.150 |
Why?
| | RNA Nucleotidyltransferases | 1 | 2019 | 23 | 0.150 |
Why?
| | Telomere | 1 | 2022 | 288 | 0.150 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1496 | 0.150 |
Why?
| | Coinfection | 1 | 2020 | 141 | 0.150 |
Why?
| | Cell Tracking | 1 | 2019 | 19 | 0.150 |
Why?
| | Ribonucleases | 1 | 2019 | 49 | 0.150 |
Why?
| | HCT116 Cells | 1 | 2019 | 78 | 0.140 |
Why?
| | Signal Transduction | 2 | 2025 | 5226 | 0.140 |
Why?
| | Ribonuclease III | 1 | 2019 | 44 | 0.140 |
Why?
| | Microscopy, Confocal | 1 | 2020 | 321 | 0.140 |
Why?
| | Etoposide | 1 | 2019 | 166 | 0.140 |
Why?
| | Viral Proteins | 1 | 2021 | 355 | 0.140 |
Why?
| | Alternative Splicing | 1 | 2020 | 247 | 0.140 |
Why?
| | Sarcomeres | 1 | 2018 | 98 | 0.140 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 628 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 634 | 0.140 |
Why?
| | Cytoplasm | 1 | 2018 | 269 | 0.130 |
Why?
| | Genome, Viral | 1 | 2019 | 218 | 0.130 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2018 | 99 | 0.130 |
Why?
| | Metagenomics | 2 | 2020 | 181 | 0.130 |
Why?
| | Disease Progression | 1 | 2025 | 2847 | 0.130 |
Why?
| | Adenosine Triphosphate | 1 | 2020 | 498 | 0.130 |
Why?
| | Prevalence | 2 | 2021 | 2834 | 0.130 |
Why?
| | Walker-Warburg Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
| | Mallory Bodies | 1 | 2016 | 1 | 0.120 |
Why?
| | Hypoxia | 1 | 2024 | 1199 | 0.120 |
Why?
| | Doxorubicin | 1 | 2019 | 397 | 0.120 |
Why?
| | NAD | 1 | 2016 | 81 | 0.120 |
Why?
| | Dwarfism | 1 | 2016 | 15 | 0.120 |
Why?
| | Osteochondrodysplasias | 1 | 2016 | 20 | 0.120 |
Why?
| | Muscular Dystrophies | 1 | 2016 | 30 | 0.120 |
Why?
| | Sodium Azide | 1 | 2016 | 6 | 0.120 |
Why?
| | Computer Simulation | 1 | 2021 | 1025 | 0.120 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 65 | 0.120 |
Why?
| | Rabbits | 1 | 2017 | 648 | 0.120 |
Why?
| | Heterogeneous Nuclear Ribonucleoprotein A1 | 1 | 2015 | 5 | 0.120 |
Why?
| | Yeasts | 1 | 2016 | 52 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1985 | 0.120 |
Why?
| | Hair | 1 | 2016 | 88 | 0.120 |
Why?
| | Fluorescence Recovery After Photobleaching | 1 | 2015 | 20 | 0.120 |
Why?
| | Molecular Mimicry | 1 | 2015 | 37 | 0.120 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2015 | 26 | 0.110 |
Why?
| | RNA Precursors | 1 | 2016 | 156 | 0.110 |
Why?
| | Disease | 1 | 2016 | 98 | 0.110 |
Why?
| | Microcephaly | 1 | 2016 | 103 | 0.110 |
Why?
| | Neuronal Plasticity | 1 | 2018 | 309 | 0.110 |
Why?
| | Solutions | 1 | 2015 | 166 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 442 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2016 | 186 | 0.110 |
Why?
| | Hirschsprung Disease | 1 | 2016 | 91 | 0.110 |
Why?
| | Sodium Chloride | 1 | 2015 | 141 | 0.110 |
Why?
| | RNA Splice Sites | 1 | 2014 | 50 | 0.110 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4557 | 0.110 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2014 | 22 | 0.110 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2014 | 13 | 0.110 |
Why?
| | Contig Mapping | 1 | 2014 | 10 | 0.110 |
Why?
| | Alleles | 1 | 2017 | 879 | 0.110 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 148 | 0.100 |
Why?
| | Quality Control | 1 | 2014 | 163 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 1 | 2020 | 660 | 0.100 |
Why?
| | Introns | 1 | 2014 | 254 | 0.100 |
Why?
| | Water Microbiology | 1 | 2014 | 90 | 0.100 |
Why?
| | Scoliosis | 1 | 2016 | 223 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 336 | 0.100 |
Why?
| | Cytokines | 1 | 2021 | 2061 | 0.100 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 862 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1455 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3409 | 0.090 |
Why?
| | Repressor Proteins | 1 | 2016 | 437 | 0.090 |
Why?
| | DNA Repair | 1 | 2014 | 256 | 0.090 |
Why?
| | Antibodies | 1 | 2014 | 401 | 0.090 |
Why?
| | Blotting, Western | 1 | 2014 | 1187 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 536 | 0.090 |
Why?
| | Nucleic Acid Conformation | 1 | 2014 | 726 | 0.090 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 824 | 0.080 |
Why?
| | Escherichia coli | 1 | 2015 | 854 | 0.080 |
Why?
| | Base Sequence | 1 | 2014 | 2190 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1490 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2015 | 654 | 0.080 |
Why?
| | Fetal Growth Retardation | 1 | 2016 | 587 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1339 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2016 | 600 | 0.080 |
Why?
| | Phenotype | 1 | 2017 | 3162 | 0.070 |
Why?
| | Female | 4 | 2021 | 78271 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2194 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 4271 | 0.060 |
Why?
| | Male | 3 | 2021 | 72315 | 0.050 |
Why?
| | Macrophage Activation | 1 | 2025 | 193 | 0.050 |
Why?
| | Animals, Zoo | 1 | 2020 | 15 | 0.040 |
Why?
| | Saliva | 1 | 2021 | 249 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2875 | 0.040 |
Why?
| | Universities | 1 | 2021 | 452 | 0.040 |
Why?
| | Luminescent Proteins | 1 | 2019 | 185 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2020 | 422 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 405 | 0.030 |
Why?
| | Colorado | 1 | 2021 | 4564 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2433 | 0.020 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|